GSK Acquires Nuvalent for $10.6 Billion; Merck and Gilead Advance Once-Weekly HIV Pill
GlaxoSmithKline agreed to acquire cancer drug developer Nuvalent for $10.6 billion to expand its oncology portfolio, particularly in lung cancer treatments. The deal represents GSK's largest acquisition in years and follows a broader trend of biopharma companies consolidating to address upcoming generic competition and strengthen drug pipelines. Meanwhile, Merck and Gilead Sciences announced their experimental once-weekly HIV combination pill met primary efficacy goals in late-stage trials, potentially offering patients a less frequent dosing alternative to daily regimens.
GlaxoSmithKline announced a $10.6 billion acquisition of Nuvalent, a cancer drug developer specializing in targeted therapies for non-small cell lung cancer. The deal marks GSK's largest acquisition in recent years and reflects the company's strategic expansion in oncology, complementing its existing focus on gynecologic cancers and multiple myeloma. Nuvalent has two drug candidates currently under FDA review for lung cancer treatment, with potential approvals expected this year. Separately, Merck and Gilead Sciences disclosed positive results from late-stage trials of an experimental once-weekly combination pill containing Merck's islatravir and Gilead's lenacapavir for HIV treatment. The combination pill demonstrated non-inferiority to standard daily regimens across two large trials and could become the first once-weekly oral HIV treatment option if approved by regulators, offering patients a more convenient alternative to current daily pills or twice-yearly injections.
What's missing
The articles do not provide financial details about GSK's funding for the acquisition or potential impact on share prices. Additionally, there is limited discussion of the competitive landscape for lung cancer treatments or how these HIV pill developments compare to existing long-acting injectable options in terms of patient adherence and real-world effectiveness.
How coverage differed
STAT News presents both developments as significant industry news within a broader context of biopharma consolidation driven by generic competition pressures. The framing is factual and business-focused, emphasizing strategic rationale and clinical significance without promotional language.
What different sources said
- STAT NewsCenter
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
Related
RFK Jr. Appointed as Health Care Affordability Official, Targets Hospital Costs
Robert F. Kennedy Jr. has been appointed to a health care affordability role and is focusing on reducing hospital costs. Kennedy, known for his work on health issues, has a non-traditional work schedule according to reporting. His appointment represents a significant shift in health care policy direction under the new administration.
U.S. Establishes Ebola Quarantine Center in Kenya Amid Local Protests and Legal Challenges
The United States is constructing a quarantine facility in Nanyuki, Kenya to isolate American citizens exposed to Ebola in Central Africa, sparking protests and a high court lawsuit from Kenyan residents who fear the virus could be introduced to their country. The facility reflects U.S. policy to prevent Ebola cases from entering the United States, though the Kenyan government has approved it as part of a bilateral partnership. Public health experts and local communities debate whether the facility enhances or undermines regional security and public health cooperation.
Study: Four Minutes of Daily Resistance Training Significantly Improves Fitness in Older Adults
A Penn State College of Medicine study published in PLOS One found that just 4 minutes of daily resistance training significantly improved strength in adults 65 and older within 12 weeks. The research suggests that even minimal daily exercise can substantially impact key health factors affecting fall risk, longevity, and independent living. The findings are notable because they demonstrate that meaningful fitness improvements for older adults may require less time commitment than commonly assumed.